Health Feb 08 CVS buys primary care provider Oak Street for $10.6 billion CVS Health is plunging deeper into providing primary care with an approximately $10.6 billion deal to acquire Oak Street Health.
Health Sep 28 Alzheimer’s drug shows promise in early results of study The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year.
Science Aug 26 Moderna sues Pfizer and BioNTech, alleges companies violated mRNA patents with COVID vaccines COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna's technology in order to make their own vaccine.
Economy Aug 08 Pfizer continues pandemic-revenue buying spree with $5.4 billion hematology deal Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic.
Health Jul 06 FDA allows pharmacists to prescribe Pfizer’s COVID-19 pill Pharmacists can prescribe the leading COVID-19 pill directly to patients under a new U.S. policy announced Wednesday that's intended to expand use of Pfizer's drug Paxlovid.
Politics Jun 28 WATCH: Biden Health Secretary Xavier Becerra pledges medication abortion access President Joe Biden's top health official said Tuesday that “every option is on the table” when it comes to helping women access abortion in the wake of the Supreme Court decision overturning Roe v. Wade.
Politics Jun 24 Federal court temporary blocks FDA ban on Juul e-cigarette sales in U.S. Juul had filed an emergency motion with the U.S. Court of Appeals in Washington so it can appeal the sales ban from the Food and Drug Administration.
Nation Jun 07 FTC begins inquiry into pharmacy benefit manager practices The Federal Trade Commission is starting an inquiry into the operations of pharmacy benefit managers who control access to prescription drugs for millions of Americans.
Economy May 03 Biogen to replace CEO after Alzheimer’s drug flops Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer's drug Aduhelm less than a year after the medication's launch triggered a backlash from experts, doctors and insurers.
Health Dec 20 Biogen cuts the price tag on its Alzheimer’s drug in half Biogen is slashing the price of its Alzheimer's treatment months after the drug debuted to widespread criticism for an initial cost that can reach $56,000 annually.